Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 165 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 165 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $157.13, for a total transaction of $11,784.75.
• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $152.80, for a total value of $11,460.00.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $188.11 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock has a market cap of $51.83 billion, a P/E ratio of 56.66, a price-to-earnings-growth ratio of 13.41 and a beta of 0.19. The stock has a 50 day moving average of $165.23 and a 200-day moving average of $160.33.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the firm earned $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Institutional Trading of Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. SHP Wealth Management bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $29,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $32,000. Finally, Meeder Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays raised their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.